Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30605654 | 0.85 | ALDH1A1 (0.59) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL718397 | 0.85 | ALDH1A1 (0.59) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL30914192 | 0.81 | KMT2A (0.56) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL14805804 | 0.81 | KMT2A (0.52) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL19848367 | 0.80 | FGFR1 (0.59) | FGFR1KMT2AHPGDALDH1A1MAPT | |
| SCHEMBL4580483 | 0.80 | FGFR1 (0.58) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL18034957 | 0.80 | KMT2A (0.55) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL19911344 | 0.79 | FGFR1 (0.56) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL11054271 | 0.79 | FGFR1 (0.56) | FGFR1KMT2AHPGDGAAALDH1A1 | |
| SCHEMBL24569506 | 0.78 | FGFR1 (0.54) | FGFR1KMT2AHPGDGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867557-B | Azepine condensed ring compound and medical application thereof | 中国医药研究开发中心有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024044570-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-115867557-A | Azepine fused ring compounds and medical application thereof | 中国医药研究开发中心有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-12-29 | — | — | US | disclosed |
| WO-2022250790-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022237890-A1 | AZEPINE-TYPE FUSED RING COMPOUND AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2022-11-17 | — | — | WO | disclosed |
| EP-3740474-B1 | AGRICULTURAL CHEMICALS | GLOBACHEM NV (BE) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
| EP-0873292-B1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEM PLASTIC (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-0873292-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5731472-A | HETEROCYCLIC NITROGEN COMPOUNDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997020798-A1 | IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1997-06-12 | — | — | WO | disclosed |
| US-4975362-A | Silver halide emulsion and a cyanine dye for use with diode lasers | EASTMAN KODAK COMPANY (US) | 1990-12-04 | — | — | US | disclosed |
| US-4965182-A | CYANINE DYES | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-23 | — | — | US | disclosed |
| US-4801525-A | CYANINE DYES, LIGHT-INSENSITIVE HYDROPHILIC COLLOID LAYER | FUJI PHOTO FILM CO., LTD. (JP) | 1989-01-31 | — | — | US | disclosed |
| US-4460709-A | Process for producing oxygen-containing organic compounds | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1984-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411422-A1 | ERBB RECEPTOR INHIBITORS | ERBB2, EGFR, ERBB3 | FGFR1 18/4885KMT2A 3120/4885HPGD 1796/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | FGFR1 1841/4885KMT2A 191/4885HPGD 553/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | FGFR1 1783/4885KMT2A 2371/4885HPGD 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.